The Experts below are selected from a list of 4038 Experts worldwide ranked by ideXlab platform
Zou Min-shu - One of the best experts on this subject based on the ideXlab platform.
-
Transforming Growth Factor-β_1 and Its Clinical Significances in Patients with Primary Nephritic Syndrome
Journal of Elinical Research, 2005Co-Authors: Zou Min-shuAbstract:[Objective]To measure the level of urinary TGF-β1 and evaluate its clinical significances in patients with primary Nephritic Syndrome. [Methods]The urinary TGF-β1 levels were measured by sensitive enzyme-linked immunosorbent assay (ELISA) in 38 children with Nephritic Syndrome treated with prednisone or/and cyclophosphamide. [Results]Twenty two patients responded sensitively to prednisone, whose urinary TGF-β1 was decreased after complete remission by prednisone treatment[(363.8±187.6) vs (234.5±113.2) ng/mgCr,( P 0.01)].In 16 patients with steroid-resistant,the levels of urinary TGF-β1 were not decreased after standard course of treatment with prednisone[(374.5±193.5) vs (353.9±173.3) ng/mgCr, P 0.05 )],however,complete remission of Nephritic Syndrome as cyclophosphamide pulse treatment was added in 10 patients[(376.6±180.3) vs (208.5±102.7) ng/mgCr,( P 0.05)]. The levels of urinary TGF-β1 showed a positive correlation with albumin(r=0.480, P 0.01),total urine protein excretion/24h(r= 0.419, P 0.01). [Conclusion ]The levels of urinary TGF-β1 can be seen as predictor in reflecting disease activity,estimating therapeutic effect in patients with Nephritic Syndrome.
Wu Chao-qin - One of the best experts on this subject based on the ideXlab platform.
-
Effect of Magnesium Isoglycyrrhizinate on Treatment of Liver Injury Caused by Cyclophosphamide in Refractory Nephritic Syndrome Patients
Guangxi Medical Journal, 2014Co-Authors: Wu Chao-qinAbstract:Objective To explore the effect of magnesium isoglycyrrhizinate on the treatment of liver injury caused by cyclophosphamide in refractory Nephritic Syndrome patients. Methods Sixty-three refractory Nephritic Syndrome patients with liver injury caused by cyclophosphamide were divided into treatment group( 30 cases) and control group( 33 cases)according to the random number table. The treatment group was treated with the intravenous drip of magnesium isoglycyrrhizinate,and the control group was treated with the intravenous drip of reduced glutathione,the treatment lasted for 2weeks in both groups. The serum glutamic-pyruvic transaminase( ALT),glutamic-oxalacetic transaminease( AST),total bilirubin( TBIL) and albumin( ALB) before and after the treatment as well as therapeutic effects and drug adverse reactions were observed. Results The signs and symptoms of both groups became normal in most of the patients after treatment,the recovery rate of fatigability,anorexia,abdominal distension,discomfort in liver area and hepatomegaly showed no significant difference between two groups( P 0. 05). There was no significant difference in the serum levels of ALT,AST,TBIL,ALB before treatment between two groups( P 0. 05). The serum levels of ALT,AST,TBIL after treatment were significantly lower than those before treatment in both groups( P 0. 05),but the serum level of ALB showed no significant changes( P 0. 05). The serum levels of ALT,ALB of treatment group were significantly lower than those of control group aftertreatment( P 0. 05),but the serum levels of AST,TBIL after treatment showed no significant difference between two groups( P 0.05). The total effective rate was 96. 7% in the treatment group,which was 84. 8% in the control group,the therapeutic effect of treatment group was significantly better than that of control group( P 0. 05). No severe adverse events occurred in both groups. Conclusion Magnesium isoglycyrrhizinate has better effects on the treatment of liver injury caused by cyclophosphamide in refractory Nephritic Syndrome patients,and it has no severe adverse reactions.
Li Bao-hua - One of the best experts on this subject based on the ideXlab platform.
-
Effect of tetragenous treatment on serum interleukin-6, tumor necrosis factor-alpha in refractory Nephritic Syndrome
Journal of Xinjiang Medical University, 2007Co-Authors: Li Bao-huaAbstract:Objective: To investigate the effect of IL-6 and TNF-α in refractory nephrotic Syndrome treated by tetragenous treatment of prednisone, cyclophosphamide, angiotensin Ⅱ receptor antagonist and Low molecular weight heparin. Methods: The levels of IL-6 and TNF-α were evaluated by enzyme-linked immunosorbent assay (ELISA) on both pretreatment and post-treatment groups, and supervise the changes of 24 hours urinary protein, serum albumin and lipid. Results: Serum IL-6 and TNF-α levels were higher in pre-treatment group than those in normal control group (P0.05). After tetragenous treatment, IL-6 and TNF-αlevels decreased (P0.05), 24 h urinary protein, serum lipid significantly decreased (P0.05), and albumin level significantly increased (P0.05). There were significant differences in TNF-α, 24 h urinary protein and serum albumin (P0.05) except IL-6 and lipid (P0.05) in both post-treatment and normal control groups. Conclusion: This study demonstrated that there were unnormal serum IL-6 and TNF-α levels in patients with refractory Nephritic Syndrome, tetragenous treatment could significantly inhibit the expression of activated IL-6 and TNF-α, reduce 24 h urinary protein, serum lipid level and increase serum albumin level, tetragenous treatment could alleviate refractory Nephritic Syndrome.
Jiang Shufang - One of the best experts on this subject based on the ideXlab platform.
-
Clinical features and disposal strategies of Nephritic Syndrome during pregnancy
Journal of Binzhou Medical University, 2007Co-Authors: Jiang ShufangAbstract:Objective To analyze the clinical features of Nephritic Syndrome during pregnancy(NSP) and approach its disposal strategies.Methods Retrospective analysis was taken to 42 cases of NSP from 2002 to 2006,including their pregnancy outcomes,complications,modalities of termination of pregnancy,Perinatal outcomes and therapy methods.Results 38 pregnancy women complicating ascitic fluid,34 terminations of pregnancy by uterine-incision delivery,8 inductions of labor with water bag,6 perinatal deaths.Conclusion Severe dropsy and ascitic liuid are outstanding features of NSP,2 complication during pregnancy,by which mother and infants prognosis was severely influenced,and diagnosis earlier and disposal properly is the key point to improve mother and infants results.
Liu Yun - One of the best experts on this subject based on the ideXlab platform.
-
Leflunomide in treating purpura nephritis with Nephritic Syndrome
Journal of Modern Urology, 2009Co-Authors: Liu YunAbstract:Objective To observe the efficacy and safety of leflunomide in treating purpura nephritis with nephrotic Syndrome (NS). Methods 38 allergic purpura nephritis patients were randomly chosen,including 20 male and 18 female,with a mean age of 26.2±10.6. 19 cases in the treatment group were given oral leflunomide 50 mg/d,three days later 20 mg/d,and the dosage of steroids was 1 mg/(kg·d),with a taper over eight weeks. The 19 cases in the control group used cyclophosphamide to impinge every half a month,the total amount reached 150 mg/kg,and the steroids medication was the same as the treatment group. Then the 24-hour urine protein,the RBC count of urinary sediment,and plasma albumin level after treatment were observed. Results In both groups,24-hour urine protein and the RBC count of urinary sediment were significantly decreased,and the serum albumin level were significantly increased (P0.05) after 3 and 6 months. There was no significant difference of effects in the first 3 months (P0.05),but the treatment group was obviously more effective than the control group after 6 months (P0.05). Conclusion This study data suggests that compared with cyclophosphamide,leflunomide is safer and more effective for the treatment of purpura nephritis with Nephritic Syndrome.